Loading…
← CockpitCompetitor Analysis › 300267.SZ Hunan Er-Kang Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Hunan Er-Kang Pharmaceutical Co., Ltd. Class A300267.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum weak 29
Mkt cap
$829M
US dollars, full cap
Free float
63%
of shares outstanding
$/day
$13.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-11.6 pp
WACC 7.6%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥2.72
1D-0.4%
1W-7.5%
1M-10.5%
3M-18.6%
6M-40.2%
YTD-20.2%
1Y-24.0%
ATR %3.9%
52w lowhigh46.8% off high

What Hunan Er-Kang Pharmaceutical does

Employees: 1,271

Hunan Er-Kang Pharmaceutical at a glance

Size Hunan Er-Kang Pharmaceutical (300267.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $829M, the 2515th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥2.72 on 18 Nov 2026.

Performance Over six months the shares fell 40.2%, against -8.1% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth Revenue fell 14.4% over the last twelve months (peer median +3.8%); the operating margin is -29.2% (peer median 6.7%).

Valuation It trades at 4.7× enterprise value to sales against a peer median of 3.1× (7th most expensive of 18).

Capital Return on invested capital runs 11.6 points below its cost of capital (7.6% WACC).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 90300267.SZ 59
Six months, rebased to 100: Hunan Er-Kang Pharmaceutical against the median of its 20 peers (local-currency closes).

Hunan Er-Kang Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.11BCN¥1.16BCN¥1.13BCN¥1.77BCN¥1.86B
Revenue growth—+2%-36%-5%—
Gross profitCN¥414MCN¥242MCN¥210MCN¥241MCN¥278M
EBITDAn/aCN¥140MCN¥103M-CN¥10.7MCN¥172M
Net income-CN¥347M-CN¥380M-CN¥373M-CN¥195MCN¥45.9M
Free cash flow-CN¥161MCN¥97.5M-CN¥27.0M-CN¥77.0MCN¥121M
Capital expenditureCN¥237MCN¥164MCN¥196MCN¥238MCN¥173M
Total debtCN¥702MCN¥602MCN¥517MCN¥363MCN¥401M

Quarterly statements and history in the cockpit →

Hunan Er-Kang Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-50%-25%0%+25%0008136032290020826078688621COLL688176086450SUVEN069620688073RIGLCRVSSANOFIORIC006120PHARM300267.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Hunan Er-Kang Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×250×500×750×0008136032290020826078688176086450SUVEN006120300267.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hunan Er-Kang Pharmaceutical is the large dot.

Hunan Er-Kang Pharmaceutical competitors and peer comparison

How Hunan Er-Kang Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hunan Er-Kang Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300267.SZPeer medianRank in peer set
1-month return-10.5%-7.7%10th lowest of 21
6-month return-40.2%-8.1%2nd lowest of 20
Distance from 52-week high-46.8%-37.2%6th lowest of 21
Revenue growth (TTM)-14.4%+3.8%2nd lowest of 19
Operating margin-29.2%6.7%5th lowest of 19
EV / Sales4.7×3.1×7th most expensive of 18
ROIC minus cost of capital-11.6 pp-2.3 pp4th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%4.7×n/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%13.8×n/an/a
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%6.5×n/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%7.0×27.7%-39.5%
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%1.8×4.6%+22.5%
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%5.8×n/an/a
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%2.3×-2.6%+20.3%
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%15.3×n/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%1.2×-4.2%+10.6%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%789.4×n/an/a
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%1.2×n/an/a
Bide Pharmatech 688073.SSChina$801M+10%+10%19%3.1×13.9%+27.7%
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%2.5×1.5%+22.1%
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%0.9×n/an/a
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a
Sanofi India SANOFI.NSIndia$797M0%-6%26%4.1×16.3%-8.7%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%4.1×31.7%+4.2%
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%0.8×n/an/a
Pharming PHARM.ASNetherlands$867M-6%+2%9%2.2×2.4%+12.4%

Questions

Which companies are Hunan Er-Kang Pharmaceutical's closest peers?
The cockpit's peer set: Dezhan Healthcare (000813.SZ), Zhejiang Ausun Pharmaceutical (603229.SS), Wanbangde Pharmaceutical (002082.SZ), Hygeia Healthcare (6078.HK), Beijing Sun-Novo Pharmaceutical Research (688621.SS), Collegium Pharmaceutical (COLL), Jiangsu Yahong Meditech (688176.SS), DongKook Pharmaceutical (086450.KS).
Is Hunan Er-Kang Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 4.7× against a peer median of 3.1×, 7th most expensive of 18 in its peer set.
How has Hunan Er-Kang Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -40.2% against -8.1% for the median peer; over one year -24.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.